Insomnia Treatment Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DMPH2241 | Last Updated On: Oct 31 2022 | Available Formats

> Global Insomnia Treatment Market Expected to reach a high CAGR of 5.2% By 2029: DataM Intelligence

Global Insomnia Treatment Market is segmented By Treatment Type (Over the Counter Sleep Aids, Prescription Sleep Aids), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

 

Market Overview

The "Global Insomnia Treatment Market" is expected to grow at a high CAGR of 5.2% during the forecasting period (2022-2029). 

Global Insomnia Treatment Market Scope

Metrics

Details

Market CAGR

5.2%

Segments Covered

Treatment Type, By Distribution Channel and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

Get A Free Sample Click Here

Insomnia is a sleeping disorder in which an individual has difficulty falling asleep or staying asleep. People with insomnia can feel dissatisfied with their sleep and experience symptoms such as fatigue, low energy, difficulty concentrating, mood disturbances, and decreased performance at work or at school. Insomnia disorder is an economic burden and public health concern affecting up to one-third of the population of the United States.

Market Dynamics

The global insomnia treatment market growth is driven by the increasing number of sleep disorders, affordable reimbursement scenarios for drugs prescribed in insomnia treatment, rising health awareness leading to effective insomnia treatment, and developing healthcare infrastructure.

The development of new technologies and the introduction of medical devices will drive the market growth    

The growth of the market is expected to be boosted by the development of new technologies and the introduction of medical devices. The market's major players have a significant impact on the market. For instance, the US Food and Drug Administration (FDA) approved Eisai Co. Ltd's in-house discovered orexin receptor antagonist DAYVIGO (lemborexant) CIV for the treatment of adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance in the United States in June 2020.

According to the American Psychological Association's (APA) Stress in America survey, adults in 2020 rated their stress levels as 5.0 on a scale of 1 to 10, up from 4.9 in 2019. Furthermore, stress levels among Gen Z adults have been slightly rising over the last two years, rising from 5.6 in 2018 to 5.8 in 2019, and 6.1 in 2020. Insomnia rarely occurs on its own and is frequently associated with other illnesses. Rather than treating the primary disorder, where symptoms of insomnia may go unnoticed or untreated, there is currently a push to recognize chronic insomnia as a disorder that requires treatment. Patients with insomnia are more likely to develop psychiatric disorders, such as depression and anxiety, as well as increased healthcare utilization and costs, lower quality of life, drug or alcohol abuse, poor occupational performance, and accidents.

Moreover, the growth of psychological conditions and constantly increasing noise levels in the urban areas will also propel the insomnia treatment market, during the forecast period.

The misconceptions about the seriousness of insomnia will hamper the growth of the market  

However, the misconceptions about the seriousness of insomnia and patient non adherence to the treatment are some of the factors that are expected to restrain market growth over the forecast period.   

COVID-19 Impact Analysis

The COVID-19 pandemic has produced unprecedented changes in lives. For many people, it has caused significant stress, anxiety, and concerns about health, social isolation, employment, finances, and the challenge of balancing work and family obligations for many people. Such a significant life event is likely to disrupt sleep and has an impact on market growth. The COVID-19 pandemic has impacted sleep, according to the American Academy of Sleep Medicine's (AASM) Sleep Prioritization Survey 2020, about a third of adults (33%) have noticed a change in their sleep quality, 30% have noticed a change in their ability to fall asleep, and 29% have noticed a change in their nightly amount of sleep. In addition, females were more likely to report that bedtimes (31%) are impacted by the COVID-19 pandemic than males (25%).

Furthermore, fear of the pandemic led to depression in some people globally. Thus, an increase in coronasomnia, stress, and depression associated with the COVID-19 pandemic, surges the demand for insomnia drugs and drives the growth of the market.

Segment Analysis

The orexin antagonist segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)        

The orexin antagonist tablets support the natural transition from sleeplessness to sleep by inhibiting the arousal system's wakefulness-promoting orexin neurons. Suvorexant advances sleep onset, as well as sleep maintenance. This distinctive alternative has advantageous permissibility and a restricted side-effect profile.

Suvorexant is a potent dual orexin receptor antagonist that blocks both receptors, i.e., OX1R and OX2R. It stimulates sleep through the binding inhibition of orexin-A and B, neuropeptides that promote wakefulness.

According to the study titled "Evolution of Orexin Neuropeptide System: Structure and Function" published in the Frontier in Neuroscience in July 2020, in the human brain, there are approximately 70,000 orexin neurons located in the perifornical lateral hypothalamus, which send signals throughout the brain and spinal cord. Suvorexant’s mechanism of action varies from that of benzodiazepines and non-benzodiazepines since it has no effect on Gamma-aminobutyric acid (GABA). As an alternative to promoting sleep, it inactivates wakefulness. Thus these factors are driving the growth of the segment in the forecast period.

Geographical Analysis

North America region holds the largest market share of the global insomnia treatment market

North America leads the insomnia treatment market. The growing need for sleep disorder treatment in the US and Canada coupled with the growing prevalence of sleep disorders is driving the market over the forecast period. Stress can cause adjustment insomnia, according to the American Academy of Sleep Medicine 2020, which affects up to 20% of people in the United States each year. Children with poor sleeping habits are more likely to develop behavioral insomnia, which affects 30% of children. Insomnia is caused by prescription drugs, substance abuse, medical disorders, and mental health conditions, and it affects about 3% of the population. Depression, drug withdrawal, obesity, and anemia are some of the specific causes.

Additionally, the presence of supportive organizations specific to insomnia in the country is also a major driving factor for the market. The Canadian Sleep Society is one such national organization committed to improving sleep for all Canadians through support for research, promotion of high-quality clinical care, education of professionals and the people, and advocacy for sleep and sleep disorders medicine.

Competitive Landscape

The insomnia treatment market is a moderately competitive presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include Merck & Co., Ebb Therapeutics, Paratek Pharmaceuticals, Inc., Pfizer Inc., Sanofi S.A., Electromedical Products International Inc., Takeda Pharmaceutical Company Ltd., Cerêve Inc., Innovative Neurological Devices, Eisai, Co. Ltd among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Insomnia Treatment Market globally. For instance, in January 2021, Minerva Neurosciences Inc. and Royalty Pharma plc entered into an agreement under which Royalty Pharma will acquire Minerva’s royalty interest in suvorexant. Seltorexant, a selective orexin 2 receptor antagonist, is currently in Phase 3 development for the treatment of the major depressive disorder (MDD) with insomnia symptoms.

Pfizer Inc.

Overview:

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sales, and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines.     

Product Portfolio:

HALCION:  Halcion is indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults.  The recommended dosage is 0.25 mg once daily before bedtime. A dosage of 0.125 mg once daily may be sufficient for some patients (e.g., patients with low body weight). A dosage of 0.5 mg should be used only for patients who do not respond adequately to a trial of a lower dose. The maximum recommended dosage is 0.5 mg once daily. 

Why Purchase the Report?

  • Visualize the composition of the global insomnia treatment market segmentation by treatment type, distribution channel, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in the global insomnia treatment market by analyzing trends and co-development deals.  
  • Excel data sheet with thousands of data points of global insomnia treatment market-level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.  
  • Product mapping in excel for the key product of all major market players

The global insomnia treatment market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200  pages.  

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Frequently Asked Questions

What is the Projected CAGR value of the Global Insomnia Treatment Market?

Global Insomnia Treatment Market is expected to grow at a CAGR of 5.2% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Global Insomnia Treatment Market during 2022-2029.

Which is the fastest growing region in the Global Insomnia Treatment Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period.

Trending Topics

Parkinson’s disease Therapeutics Market

Schistosomiasis Drugs Market

Insulinoma Treatment Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest